You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Timeline
Attention over time
Attention Score history
Activity
X Demographics
Mendeley demographics
Login to view Mendeley reader trends over time.
Attention Score in Context
| Title |
History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
|
|---|---|
| Published in |
Cancer Epidemiology, Biomarkers & Prevention, August 2017
|
| DOI | 10.1158/1055-9965.epi-17-0367 |
| Pubmed ID | |
| Authors |
Albina N. Minlikeeva, on behalf of the Ovarian Cancer Association Consortium, Jo L. Freudenheim, Kevin H. Eng, Rikki A. Cannioto, Grace Friel, J. Brian Szender, Brahm Segal, Kunle Odunsi, Paul Mayor, Brenda Diergaarde, Emese Zsiros, Linda E. Kelemen, Martin Köbel, Helen Steed, Anna deFazio, on behalf of the Australian Ovarian Cancer Study Group, Susan J. Jordan, Peter A. Fasching, Matthias W. Beckmann, Harvey A. Risch, Mary Anne Rossing, Jennifer A. Doherty, Jenny Chang-Claude, Marc T. Goodman, Thilo Dörk, Robert Edwards, Francesmary Modugno, Roberta B. Ness, Keitaro Matsuo, Mika Mizuno, Beth Y. Karlan, Ellen L. Goode, Susanne K. Kjær, Estrid Høgdall, Joellen M. Schildkraut, Kathryn L. Terry, Daniel W. Cramer, Elisa V. Bandera, Lisa E. Paddock, Lambertus A. Kiemeney, Leon F.A.G. Massuger, Rebecca Sutphen, Hoda Anton-Culver, Argyrios Ziogas, Usha Menon, Simon A. Gayther, Susan J. Ramus, Aleksandra Gentry-Maharaj, Celeste L. Pearce, Anna H. Wu, Jolanta Kupryjanczyk, Allan Jensen, Penelope M. Webb, Kirsten B. Moysich |
| Abstract |
Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470-3. ©2017 AACR. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley demographics
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 77 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 14% |
| Student > Ph. D. Student | 10 | 13% |
| Student > Bachelor | 7 | 9% |
| Student > Doctoral Student | 6 | 8% |
| Student > Master | 5 | 6% |
| Other | 12 | 16% |
| Unknown | 26 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 34% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Immunology and Microbiology | 2 | 3% |
| Other | 11 | 14% |
| Unknown | 28 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2018.
All research outputs
#28,565,680
of 34,350,842 outputs
Outputs from Cancer Epidemiology, Biomarkers & Prevention
#5,015
of 6,183 outputs
Outputs of similar age
#285,213
of 354,930 outputs
Outputs of similar age from Cancer Epidemiology, Biomarkers & Prevention
#43
of 54 outputs
Altmetric has tracked 34,350,842 research outputs across all sources so far. This one is in the 9th percentile – i.e., 9% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,183 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.4. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 354,930 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.